BLRX Latest Press Releases

-- July 20, 2026 --

BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026 PRNewswire 7:00 AM

-- July 8, 2026 --

BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model PRNewswire 7:00 AM

-- May 27, 2026 --

BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update PRNewswire 7:00 AM

-- May 22, 2026 --

BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting PRNewswire 7:00 AM

-- May 20, 2026 --

BioLineRx to Report First Quarter 2026 Results on May 27, 2026 PRNewswire 7:01 AM

-- May 19, 2026 --

BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts PRNewswire 7:00 AM

-- April 28, 2026 --

BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) PRNewswire 7:00 AM

-- March 26, 2026 --

BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) PRNewswire 7:00 AM

-- March 23, 2026 --

BioLineRx Reports 2025 Financial Results and Provides Corporate Update PRNewswire 7:00 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software